Alpha Tau Medical Ltd
DRTS
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.4B
$15.03
▲ +2.80%
P/E
-22.43
Mkt Cap
$1.4B
52-Wk Range
$3.43–$15.17
52-Week Range
$3.43 - $15.17
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 307.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary Alpha-DaRT technology with unique mechanism of action in oncology
- First-mover advantage in alpha-particle radiation therapy for solid tumors
- Diversified clinical pipeline across multiple cancer indications
- Strong intellectual property portfolio protecting core technology and applications
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Advancement of clinical trials and potential FDA approvals for multiple indications
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+62.0% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying DRTS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 19, 2026
AUG 10, 2026
Reported EPS of -$0.50 vs -$0.14 consensus (-254.9% surprise). Revenue of $100.0K vs $144.5K expected (-30.8%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-254.9%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
5 analysts · 80% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
80%
Hold
20%
Sell
0%
Median Price Target
—
Latest: Barclays · Sep 3, 2026
vs Industry
How DRTS stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related